Background. Whereas in Europe most of Toxoplasma gondii genotypes belong to the type II lineage, in Latin America, type II is rare and atypical strains predominate. In North America, data on T. gondii genotypes in humans are scarce.
Toxoplasma gondii is a protozoan parasite with worldwide distribution that can infect virtually all warm-blooded animals. In humans, infection is usually asymptomatic in healthy individuals, but severe diseases can be observed in immunocompromised patients, in fetuses, and occasionally in immunocompetent individuals [1] . When toxoplasmosis is symptomatic, severe outcomes in immunocompetent individuals can potentially be related to various factors, including host genetics and immune system responses and, as suggested by several studies, the genotype of the parasite [2] [3] [4] [5] [6] . The hypothesis proposing a link between parasite genotype and disease severity in humans has primarily emerged from studies in Latin America, where a rich genetic diversity and predominance of atypical strains of T. gondii are found [7] [8] [9] . In contrast, in Europe, where most T. gondii samples belong to the type II lineage, the correlation between T. gondii strains and severe disease has been reported to a lesser extent and, in immunocompromised patients an association between genotype and clinical outcomes has not been identified [10] .
In North America, T. gondii was initially considered to have a clonal population structure with low genetic diversity comprising 3 main lineages (types I, II, and III) [11] . Thus, it was thought that the population structure of T. gondii samples infecting humans in North America was very similar to that of Europe, with a predominance of type II and III genotypes and with atypical genotypes being relatively rare and likely to be imported from abroad [10] [11] [12] . However, recent studies performed in wildlife from North America revealed a high prevalence of an atypical haplogroup 12 (HG12) lineage, highlighting that T. gondii genetic diversity in North America could be higher than suspected [13, 14] . In meat for human consumption, a higher T. gondii diversity than in Europe has also been reported, suggesting that this should also be the case in humans infected with T. gondii in North America [15, 16] . To our knowledge, there are very few T. gondii genotyping data from humans in North America, with the majority of data coming from serotyping studies [11, 17, 18] . Serotyping performed in serum samples from congenitally infected infants from the United States revealed that 39 % of the samples were serotype II whereas 61% were not exclusively type II serotypes [17] .
These results are also suggestive that in North America the parasite diversity is greater than was initially suspected. Data from genotyping are likely to be more accurate, because genotyping allows discrimination between closely related genotypes. Microsatellites analysis provides information not only on genotypic characterization at typing level (types I, II, and III vs atypical) but also at the fingerprinting level (genetic distance between types) [19] . In this study, we genotyped a collection of T. gondii DNA samples obtained from patients with toxoplasmosis diagnosed at the Palo Alto Medical Foundation Toxoplasma Serology Laboratory (PAMF-TSL), a National Reference Center for the study and diagnosis of toxoplasmosis in the United States. Associations between genotype and clinical data were studied. Because it was difficult to have accurate information concerning where patients could have been infected, we used discriminant analysis of principal components (DAPC) in an attempt to infer each atypical genotype to a specific geographic area where patients were likely infected [20] . To our knowledge, this is the first time DAPC has been applied for T. gondii genotyping data.
MATERIALS AND METHODS

Clinical Samples, Polymerase Chain Reaction Assay, and Serology
Sixty-seven consecutive T. gondii polymerase chain reaction (PCR)-positive DNA samples from 67 patients were available for genotyping. Samples from 2002 to 2015 were obtained from remaining DNA that had been used for PCR testing in samples submitted for diagnostic purposes to the PAMF-TSL. The decision to perform invasive procedures to obtain these specimens were made by the referring physician solely on the basis of what was clinically indicated and not for the purpose of this report.
Among the 67 patients, clinical and/or serological data were consistent with a postnatally acquired infection (acute infection or reactivation of a past infection) in 49 patients and with congenitally acquired infection in 18 patients. All patients lived in North America at the time of sampling (60 in the United States and 7 in Canada). Patients with postnatally acquired infection were 5-87 years of age. Immune status and disease severity are described in Supplementary Table 1 . Briefly, 15 patients had human immunodeficiency virus (HIV) infection, 14 were immunocompromised not due to HIV infection, 8 were immunocompetent, and 12 had unknown immune status. The tested samples included 22 ocular fluid (aqueous humor, vitreous fluid), 10 brain biopsy, 10 cerebrospinal fluid, 3 whole blood, 3 bronchoalveolar lavage, and 1 serum sample.
Congenital infection was diagnosed in the antenatal period by means of PCR in amniotic fluid samples and in the postnatal period by means of PCR in cerebrospinal fluid or whole blood samples in 7 and 11 patients, respectively (Supplementary Table 2 ). In 14 cases of congenital toxoplasmosis, clinical information was available and clinical signs of the disease were present (Supplementary Table 2 ).
At the time of diagnosis, PCR was performed as described elsewhere [21] . Extraction was performed as described by Olariu et al [21] 
Genotyping Analyses With Microsatellite Markers
The 67 T. gondii DNA extracted from clinical samples were genotyped using 15 microsatellite markers distributed on 10 of 14 chromosomes, as described elsewhere [19] . We also included the genotyping data of 6 isolates (ROD, VEG, SOU, ARI, RAY, and CAST) from US patients with toxoplasmosis diagnosed in the 1990s and extensively studied in genetic studies since then [11, 18] . The GT1, ME49, and CTG strains were used as T. gondii type I, II, and III reference strains, respectively [18] .
Neighbor-Joining Clustering
The unrooted neighbor-joining trees was reconstructed from microsatellite data with Populations 1.2.32 software (http:// bioinformatics.org/populations/), based the chord-distance estimator described by on Cavalli-Sforza and Edwards [26] and generated with MEGA 6.05 software (http://www.megasoftware. net/history.php).
Association of Clinical Factors and Genotype
Logistic regression analysis was performed separately for 2 outcomes: presence or absence of atypical genotype and presence or absence of disease severity. The first outcome was regressed on 3 candidate predictors of geographic location (eastern vs western United States), immune status (immunocompetent vs immunocompromised), and infection type (congenital, acute, or reactivation). The second outcome (disease severity) was regressed on the presence or absence of atypical genotype. For the outcome of disease severity, ocular toxoplasmosis served as the comparator for cerebral and disseminated toxoplasmosis.
Freeman-Halton exact testing permitted assessment of genotypic (type II, type III, or atypical) association with geographic location (east vs west [17] ), immune status, and disease severity.
Before analysis, missing clinical data were multiply imputed [27] , with 1000 complete data sets imputed under each of 2 assumptions, that data were either missing at random or missing not at random [28] , with sensitivity analyses performed for the latter [29] , under the assumption that acute infections were more likely to be missing than other infection types because they were the least common (acute infection in 10% of participants, congenital in 27%, and reactivation in 41%; infection type missing in 22%). Logistic regression was bias corrected [30] . A profile-likelihood confidence interval was constructed for each logistic regression coefficient estimate because these have been recommended for their accuracy under bias-corrected logistic regression [31] . Hypothesis test results are declared statistically significant at P < .05. All analyses were performed using SAS software (version 9.4; SAS Institute) and using the logistf package (version 1.22; https://CRAN.R-project.org/package=logistf) in R software (version 3.4.0; https://www.R-project.org) [32] .
Geographic Assignment of Atypical T. gondii Genotypes With DAPC
Because epidemiological data for patients (eg, birthplace and travel history) were not available, we conducted a DAPC to infer the geographic origin of T. gondii DNA samples with atypical genotypes based on microsatellite markers identified in human patients in North America. To perform this estimation, a reference population is required. Samples from animals constitute a good reference population, because this population is not highly subject to travel, unlike humans. We used 3 geographically distinct populations of 167 T. gondii samples, from both wild and domestic animals as putative populations of origin for atypical T. gondii DNA samples in humans in North America. The 3 populations consisted of 33, 113, and 21 T. gondii samples from North America, Latin America, and Asia (China), respectively (Supplementary Figure 1 and Supplementary Table 3 ). These 3 populations were designed to be representative of the local (ie, endemic) genetic diversity, from which patients might have acquired atypical genotypes.
We genetically discriminated these 3 populations using DAPC [20] . Briefly, DAPC was used to (1) identify the optimal number of principal components (PCs) to use in DAPC through a cross-validation procedure to avoid overfitting, (2) find the discriminant function (DF) that best separates the 3 geographically distinct populations of T. gondii samples in animals and calculate each individual membership probability, and (3) assign the atypical isolates T. gondii DNA samples from humans to a given geographic origin, using the above DF. Twofold cross-validation was performed using 70% (n = 117) of the 167 animal T. gondii samples collection as a training set, and estimates of variations of the assignment success rate (ASR) and its root mean squared error with the number of retained PCs were performed using the remaining 30% animal T. gondii samples (ie, validation set).
For each number of PCs, 30 random partitions into training and validation sets were performed. We selected as the optimal number of PCs the number for which the root mean squared error was the lowest. The indicator of discrimination performance was defined by the overall ASR as the ratio of the number of correctly assigned animal T. gondii samples to the total number of animal T. gondii samples. A T. gondii sample was assigned to the geographic population for which its estimated membership probability was the highest, and we used the DF to assign every atypical T. gondii DNA sample in humans in North America to its most likely geographic population of origin. For types II and III genotypes, DAPC was tested, and it was not possible to assign a geographic area for these genotypes that do not cluster geographically because they are globally distributed (data not shown). DAPC was performed using the dapc function of the adegenet 2.0.0 library [33] in R software (version 3.4.0; https://www.R-project.org) [34] .
RESULTS
Genotyping Analyses With Microsatellite Markers and Neighbor-Joining
Clustering
The genotyping results of T. gondii DNA extracted from clinical samples of 67 patients collected in this study, of 6 historical isolates collected in humans in the United States in the 1990s (ROD, VEG, SOU, ARI, RAY, and CAST), and of 3 reference type I, II, and III strains (GT1, ME49, and CTG, respectively), are listed in Supplementary Table 4 . Of the 67 patients, 41 had T. gondii genotyping results that were considered interpretable (ie, with ≥5 microsatellite markers amplified). Of these 41 patients, 30 had postnatally acquired infection and 11 had congenital toxoplasmosis (Supplementary Tables 1 and 2 ). Of these 41 patients, 18 (43.9%) and 5 (12.2%) were infected with T. gondii with genotypes clustered with the ME49 type II strain and the CTG type III strain in the neighbor-joining tree, respectively ( Figure 1 and Supplementary Table 4 ). The remaining 18 patients (43.9%) were infected with non-type I, II, or III genotypes and therefore designated as atypical (Figure 1 and Supplementary Table 4 ). Of the 6 historical isolates, 2 were in the type III group (VEG and ROD), 3 were atypical (ARI, RAY and CAST), and 1 (SOU) had a mixed II/III genotype ( Figure 1 and Supplementary Table 4 ).
Disease Severity, Geographic Distribution, and Genotyping Data
Among the 41 patients with available T. gondii genotypes, we analyzed the association between genotype (atypical vs other genotype), disease severity (cerebral, ocular, or disseminated toxoplasmosis), the type of infection (reactivation, acute infection, or congenital infection), and the patient's geographic location (Figure 2) . Findings are the same whether we assumed data are missing at random or not at random. Namely, none of the predictors examined are associated with atypical strain as outcome (west vs east, P ≥ .23; immune status, P ≥ .14; infection type, P ≥ .51), and atypical genotype is not predictive of severity (P ≥ .51). In addition, we explored the association between each genotype (type II, type III, or atypical) and disease severity (cerebral, ocular, and disseminated toxoplasmosis), immune status, and geographic location of patients without finding any association in this sample (Table 1) .
Geographic Assignment of Atypical T. gondii Genotypes With DAPC
A total of 21 T. gondii DNA samples with atypical genotypes (18 DNA samples from this study plus 3 from US historical cases) were submitted to DAPC analysis to estimate their geographic origin (North America, Latin America, or Asia). DAPC was performed using 50 PCs following cross-validation results. The 3 geographically distinct populations of T. gondii samples from animals were also genetically distinct ( Figure 3 and Supplementary Figure 1) , and the estimated overall ASR of the DAPC was very high (164 of 167 correctly assigned T. gondii samples from animals; ASR, 98.20%).
Using the DF to assign each of the 21 T. gondii DNA samples with atypical genotypes collected in humans in North America led to the following results. Eleven T. gondii DNA samples originated from Latin America, 9 from North America, and 1 from Asia (China) ( Table 2 ). Of note, among the 9 patients with atypical genotypes and reactivation, 6 were from Latin America. Overall, membership probabilities to their population of origin were high (mean [standard deviation], 0.9654 [0.1046]) ( Table 2 ) with 19 of the 21 T. gondii DNA samples having a membership probability >0.95. Two genotypes showed lower membership probability to their population of origin (North America, patients 39 and 52) ( Table 2 ) with probabilities more evenly distributed over North American and Latin American populations.
Analysis of Neighbor-Joining Tree According to DAPC Results
Atypical T. gondii genotypes acquired in North and Latin America were also clearly separated in the Neighbor-Joining tree (Figure 1) . Two populations of atypical genotypes were identified in North America. The first population included the genotypes of patients 4, 24, and 39, which clustered with the RAY isolate, and the genotype of patient 38, which clustered with the ARI isolate. Both RAY and ARI isolates were characterized as belonging to the haplogroup 12 (HG12) by intron sequencing [18] . Although there is substantial polymorphism within this group, HG12 is also known as the fourth clonal lineage [14] , and it is likely that patients 4, 24, 38, and 39 were infected with HG12 clonal lineage, because their genotypes with microsatellite markers are similar to those from other HG12 genotypes collected from North American wildlife (Supplementary Tables 3 and 4) .
The second population of atypical North American genotypes included 3 T. gondii DNA samples collected from patients 20, 33, and 52. If the exact genetic divergence of the genotype of patient 20 with other T. gondii samples remains to be clarified because of incomplete genotyping data, the genotypes of patients 33 and 52 appeared highly similar to each other and to other genotypes from North American wildlife. Of the 15 microsatellite markers used to genotype T. gondii DNA, only 1 (N60) can differentiate between the genotypes characterized from patients 33 and 52 and those from a black bear in Quebec (TgBBeCa01) and 2 red foxes in Pennsylvania (TgFoxPa06 and 08) (Supplementary Tables 3 and 4) . Atypical genotypes from Latin America were divergent from the genotypes of all other strains. The atypical genotype from patient 29 belonged to the Chinese 1 genotype that is very common in humans and animals in China [35] .
DISCUSSION
The main purpose of this study was to genotype T. gondii isolates from cases of human toxoplasmosis in North America and to seek a correlation between strain types and geographic origin, disease severity, and congenital versus postnatally acquired infections. The PAMF-TSL as the reference center for toxoplasmosis in the United States gathers diagnostic human specimens across the country. Of our 67 samples, 41 DNA samples were successfully genotyped by microsatellites. Of these samples, 43.9% were infected by type II, 12.2% by type III, and 43.9% by atypical genotypes. These data reflect a greater diversity of T. gondii genotypes present in the human population from North America even if all of the atypical T. gondii isolates were not acquired locally, as demonstrated by DAPC analysis. This genetic diversity is much richer than that found in Europe, particularly when compared with the genetic structure reported from France where type II represents >90% of the genotypes [36] . The use of DAPC provided new insights on the geographic distribution of atypical T. gondii genotypes. With the DAPC analysis, we were able to compensate for the lack of information on patients' birthplace and travel history. From this analysis, we estimated that, although some of the atypical genotypes were acquired in North America, others were imported from abroad (Latin America and Asia). Two groups of atypical genotypes endemic in humans in North America were found. From our preliminary data, we estimate that T. gondii DNA samples belonging to the HG12 are not only common in North American wildlife but are also common in humans in this area, as suggested by serotyping analyses [17, 37] . Whether T. gondii belonging to HG12 genotype is more pathogenic to humans than type II remains to be clarified.
We also highlighted a potential fifth clonal lineage in North America with at least 2 patients and 3 wild animals infected by genetically closely related genotypes in different places and at different times [38, 39] . This unexpectedly higher genetic diversity of T. gondii in North American patients has been demonstrated in a recent study with animal samples from 2 populations in Minnesota and Pennsylvania that could be even more genetically diverse than those from some areas of Brazil, for example, northeast Brazil [40] . Moreover, DAPC also allowed us to correct some misinformation on the geographic origin of T. gondii genotypes collected from clinical samples. Indeed, the CAST isolate that was characterized as haplogroup 7 by intron sequencing and was always believed to be a North American isolate is in fact from Latin America [18] . This patient with acquired immune deficiency syndrome likely acquired during childhood in Latin America T. gondii infection and later the disease reactivated in the USA. The same process occured probably for all the immunocompromised patients with atypical T. gondii genotypes acquired in Latin America in the present study.
In our study, clinical and geographic candidate predictors were categorical variables with missing data. Categorical variables are coarse resolution, which limits statistical power. With multiple imputations, we partially addressed reduction in effective sample size and bias due to missing data. With these caveats, we did not find any evidence of associations between T. gondii genotypes and type of infection, immune status, disease severity, or geographic location of the patient. In addition, we do not have any DNA from healthy infected persons. This is a limitation in genotyping studies, in which asymptomatic infections represent the majority of cases and symptomatic cases may represent a tiny minority [41] .
Direct measurements of immune system function and composition, especially those obtained longitudinally, would have provided a more objective, quantitative, and sensitive assessment of severity. However, recent studies support a causal link between T. gondii genotypes and disease severity, especially in otherwise healthy persons infected in a specific epidemiological context, for example, after consumption of raw horsemeat or wild game in the Amazonian rain forest [7, 9, 12, 42, 43] . Several studies highlighted links between severity of disease and Latin American genotypes [44, 45] . In addition, data from serotyping in congenital toxoplasmosis in North America highlighted greater pathogenicity (prematurity and severe disease at birth) when serotypes were not exclusively type II [17, 46] . In our study, it remains unclear whether physicians should take into account the genotype of the T. gondii found in clinical samples for clinical management of patients. Our sample size was modest, with multiple variables of interest. Larger samples with less missing data could yield more clinically meaningful conclusions.
In our study, we used DAPC to attribute atypical genotypes to a geographic area. With this new approach we were able to highlight that atypical genotypes are endemic in humans in North America and, in addition we corrected some misclassifications. The results from this study provide useful insights on atypical T. gondii genotypes from human samples from North America and highlight that genotypes circulating in North America are more diverse than previously suspected. Despite the absence of association in our study between genotype and disease severity, physicians should be aware that patients may encounter more severe disease when infected by an atypical genotype.
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